What is HC Wainwright's Estimate for DAWN FY2028 Earnings?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Stock analysts at HC Wainwright decreased their FY2028 EPS estimates for shares of Day One Biopharmaceuticals in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of $0.74 for the year, down from their previous forecast of $0.84. HC Wainwright has a "Buy" rating and a $36.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals' FY2029 earnings at $1.25 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.11. The business had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million.

A number of other brokerages also recently weighed in on DAWN. The Goldman Sachs Group lowered their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday, March 25th. Needham & Company LLC dropped their price objective on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a report on Wednesday. JPMorgan Chase & Co. reduced their target price on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Finally, Wedbush restated an "outperform" rating and set a $25.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $30.57.

Day One Biopharmaceuticals Trading Down 4.6 %

Shares of DAWN traded down $0.31 during trading hours on Thursday, reaching $6.45. 1,335,859 shares of the company's stock traded hands, compared to its average volume of 1,078,881. Day One Biopharmaceuticals has a 12 month low of $6.26 and a 12 month high of $17.14. The stock has a market cap of $653.78 million, a PE ratio of -6.26 and a beta of -1.24. The firm's 50 day simple moving average is $7.70 and its 200-day simple moving average is $11.08.

Insiders Place Their Bets

In related news, CFO Charles N. York II sold 4,370 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the transaction, the chief financial officer now directly owns 252,638 shares of the company's stock, valued at $3,021,550.48. The trade was a 1.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jeremy Bender sold 12,048 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now owns 128,015 shares of the company's stock, valued at $1,531,059.40. This represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,064 shares of company stock valued at $251,925 over the last three months. Insiders own 6.20% of the company's stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of hedge funds have recently modified their holdings of DAWN. FMR LLC increased its holdings in Day One Biopharmaceuticals by 73.9% during the 4th quarter. FMR LLC now owns 12,887,467 shares of the company's stock valued at $163,284,000 after purchasing an additional 5,475,087 shares during the period. Vanguard Group Inc. grew its holdings in shares of Day One Biopharmaceuticals by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 5,943,243 shares of the company's stock worth $47,130,000 after acquiring an additional 94,320 shares during the period. Franklin Resources Inc. grew its stake in Day One Biopharmaceuticals by 0.3% in the fourth quarter. Franklin Resources Inc. now owns 3,882,952 shares of the company's stock worth $49,197,000 after purchasing an additional 13,320 shares during the period. Estuary Capital Management LP increased its stake in shares of Day One Biopharmaceuticals by 35.5% in the 4th quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company's stock worth $47,092,000 after acquiring an additional 972,997 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its stake in shares of Day One Biopharmaceuticals by 17.0% during the fourth quarter. Pictet Asset Management Holding SA now owns 3,490,064 shares of the company's stock valued at $44,219,000 after purchasing an additional 507,398 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company's stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.